Drug-eluting balloons for coronary artery disease: an updated meta-analysis of randomized controlled trials

Abstract

Drug-eluting balloons (DEB) continue to present as a promising percutaneous intervention for the treatment of coronary artery disease (CAD) [ [1] Cortese B. Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. 2012; 161: 4-12 Abstract Full Text Full Text PDF PubMed Scopus (74) Google Scholar ]. Since we performed our meta-analysis of five randomized trials enrolling 349 patients [ [2] Yu C.M. Kwong J.S. Sanderson J.E. Drug-eluting balloons for coronary artery disease: a meta-analysis of randomized controlled trials. Int J Cardiol. Sept 20 2013; 168: 197-206 Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar ], several other studies evaluating DEB in CAD have been completed [ 3 Byrne R.A. Neumann F.J. Mehilli J. et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013; 381: 461-467 Abstract Full Text Full Text PDF PubMed Scopus (317) Google Scholar , 4 Rittger H. Brachmann J. Sinha A.M. et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012; 59: 1377-1382 Crossref PubMed Scopus (273) Google Scholar ]. Therefore, we incorporated the new evidence into an updated meta-analysis to extend the current knowledge on the efficacy and safety of DEB in patients with CAD.